Cannabidiol (CBD) – Nurse Practitioner

  Price  $6.95

  Credits  1.5

Clear


Format
The popularity of medical marijuana (also known as medical cannabis) continues to grow in the US. In 2018, over 3.5 million patients were registered to use medical cannabis; an increase from 2.6 million in March, 2016. As of January 2019, 33 states and Washington D.C., have laws legalizing medical marijuana. Ten states, Washington D.C., and Canada have legalized recreational marijuana. In addition, a growing number of states have laws specifically addressing the use of cannabidiol (CBD) for medical, as well as nonmedical, purposes. The use of Cannabis sativa by the Chinese – for its strength as a fiber (in paper, bowstrings, rope, or clothing) and its medicinal properties – has been documented as far back as 4000 years ago. Hemp and marijuana are both plants in the Cannabis sativa family; however, they differ in structure and active ingredients. The most prevalent active ingredient in marijuana is tetrahydrocannabinol (THC), known for its psychoactive effects. Cannabidiol (CBD) is the second most prevalent active ingredient in marijuana (among many other pharmacologically active cannabinoids) and is the most prevalent active ingredient in hemp. Both THC and CBD have pharmacological effects. However, unlike THC, CBD does not have euphoric or intoxicating effects. A growing body of research suggests that CBD may be beneficial for a range of medical conditions including, but not limited to, anxiety, movement disorders, pain, sleep disorders, and seizure disorders. The FDA has approved CBD (Epidiolex®) for the treatment of 2 rare childhood-onset epilepsy syndromes. The evidence for CBD use in other conditions is sparse; it is derived mainly from animal, in vitro, and small human trials. However, because of its apparent lack of side effects in low to moderate doses, there is a great interest in CBD as a natural supplement...
$6.95

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Nurse Practitioner

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

  • Summarize the legal considerations that surround marijuana and hemp plants. Describe the major active ingredients of both plants and explain how their physiological effects differ.
  • State the potential clinical uses for cannabidiol (CBD), including the products that have been FDA-approved for certain indications.
  • Discuss the clinical evidence to support the use of nonprescription CBD products.
  • Discuss safety concerns with nonprescription CBD products, including potential drug interactions.
  • Counsel a patient on what to look for in a nonprescription CBD product before purchasing it.

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
    20-878478
  • Universal Activity Number:
    Nurse Practitioner : 0798-0000-21-207-H01
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.